Trump Moves Ball On Drug Prices
President Donald Trump registered more wins on drug price reform. The White House announced that nine additional pharmaceutical companies have agreed to follow a most-favored-nation (MFN) drug pricing policy, with some of the companies throwing in several months’ worth of emergency drug supplies.
As with other drug firms, the drug companies will lower the Medicaid prices for drugs that are more expensive than they’re sold in other countries, although prices are already deeply discounted through federal and state rebate programs. The firms will also deeply discount cash-pay customers’ drugs via the TrumpRx website. The deals also guarantee MFN prices on all new innovative medicines the nine companies bring to market.
Trump has now reached deals with 14 of the 17 drug makers to which he sent letters in July demanding that they lower prices.
At the same time, the Centers for Medicare and Medicaid Services (CMS) seeks to reduce Medicare drug costs through a pair of payment demonstrations announced Friday. CMS would tie the prices Medicare Part B and Part D pay for medicines to costs in foreign countries. The Global Benchmark for Efficient Drug Pricing Model, or GLOBE, would cover Part B drugs. A second mandatory initiative called Guarding U.S. Medicare Against Rising Drug Costs Model, or GUARD, would cover Part D drugs. The agency estimates that the Part B model will save $11.9 billion in net spending over seven years. Roughly a quarter of Medicare beneficiaries will participate in the program.
The models would run from 2027 through 2031, with rebate invoicing and reconciliation continuing into 2033.
Additional articles: https://thehill.com/policy/healthcare/5657095-trump-policy-pharma-agreement/ and https://www.beckerspayer.com/payer/cms-proposes-2-medicare-drug-pricing-models/
(Some articles may require a subscription.)
#drugpricing #branddrugmakers #trump
https://www.modernhealthcare.com/politics-regulation/mh-cms-globe-guard-medicare-drug-pricing
